[Biomarkers in the diagnosis and therapy of inflammatory bowel diseases]
Hideki Iijima1, Shinichiro Shinzaki, Masahiko Tsujii
1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine.
Abstract:
Serologic and fecal biomarkers can be used in the diagnosis and management of inflammatory bowel disease (IBD). Antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins have been used in diagnosis of IBD, to distinguish Crohn's disease from ulcerative colitis, and to predict the risk of complications of Crohn's disease. C-reactive protein has been used to assess inflammatory processes and predict the course of IBD progression. Fecal markers have been studied for their ability to identify patients with IBD, assess disease activity, and predict relapse. We recently reported that oligosaccharides in IgG and leucin rich alpha 2-glycoprotein are potential biomarkers of IBD. This review addresses the potential for biomarkers to improve treatment strategies and challenges to their use.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF


